BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $AMGN readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06430866-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Eucalyptus readout (P3) · Amgen $AMGN
DESCRIPTION:Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pemb
 rolizumab)\n\nPrimary completion date: 2026-12-14 (estimated)\nOriginally 
 planned: 2025-12-04 (+12.3 months)\nPhase 3 · Oncology · Early-stage Non
 -squamous Non-small Cell Lung Cancer (NSCLC)\nEnrollment: 163 · Sites: 12
 8\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT06430866\nhttps://clinicaltrials.gov/study/NCT0643
 0866
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06430866
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858839-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MARITIME-1 readout (P3) · Amgen $AMGN
DESCRIPTION:Evaluation of Maridebart Cafraglutide in Adult Participants Wit
 hout Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\n\nPrimar
 y completion date: 2027-01-21 (estimated)\nPhase 3 · Cardio-Met · Obesit
 y\nEnrollment: 3853 · Sites: 243\n\nPrimary completion = last participant
 's primary-endpoint data collected\; topline results usually follow weeks 
 to months later. Sponsor-reported\, often an estimate. Not investment advi
 ce.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06858839\nhttps://
 clinicaltrials.gov/study/NCT06858839
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06858839
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858878-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MARITIME-2 readout (P3) · Amgen $AMGN
DESCRIPTION:Efficacy and Safety of Maridebart Cafraglutide in Adult Partici
 pants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\n\n
 Primary completion date: 2027-01-21 (estimated)\nPhase 3 · Cardio-Met · 
 Type 2 Diabetes Mellitus (T2DM)\, Obesity\, Overweight\nEnrollment: 1105 
 · Sites: 187\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://trial
 sonar.netlify.app/radar.html?nct=NCT06858878\nhttps://clinicaltrials.gov/s
 tudy/NCT06858878
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06858878
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05549258-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:Inebilizumab readout (P2) · Amgen $AMGN
DESCRIPTION:Study of Inebilizumab in Pediatric Subjects With Neuromyelitis 
 Optica Spectrum Disorder\n\nPrimary completion date: 2027-04-13 (estimated
 )\nOriginally planned: 2024-09-13 (+30.9 months)\nPhase 2 · Neuro · Neur
 omyelitis Optica Spectrum Disorder\nEnrollment: 15 · Sites: 19\n\nPrimary
  completion = last participant's primary-endpoint data collected\; topline
  results usually follow weeks to months later. Sponsor-reported\, often an
  estimate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.
 html?nct=NCT05549258\nhttps://clinicaltrials.gov/study/NCT05549258
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05549258
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700343-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270419
DTEND;VALUE=DATE:20270420
SUMMARY:Ocrelizumab (US) readout (P3) · Amgen $AMGN
DESCRIPTION:Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)\n\nPrima
 ry completion date: 2027-04-19 (estimated)\nOriginally planned: 2027-01-15
  (+3.1 months)\nPhase 3 · Neuro · Relapsing-remitting Multiple Sclerosis
  (RRMS)\nEnrollment: 152 · Sites: 109\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06700343\nhtt
 ps://clinicaltrials.gov/study/NCT06700343
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06700343
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987695-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:MARITIME-3-J readout (P3) · Amgen $AMGN
DESCRIPTION:Efficacy and Safety of Maridebart Cafraglutide in Adult Partici
 pants in Japan Who Have Obesity Disease\n\nPrimary completion date: 2027-0
 4-27 (estimated)\nOriginally planned: 2027-07-26 (-3.0 months)\nPhase 3 ·
  Cardio-Met · Obesity Disease\nEnrollment: 279 · Sites: 30\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://trialsonar.netlify.app/radar.htm
 l?nct=NCT06987695\nhttps://clinicaltrials.gov/study/NCT06987695
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06987695
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972551-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Romosozumab readout (P3) · Amgen $AMGN
DESCRIPTION:Study to Evaluate Efficacy and Safety of Romosozumab Compared W
 ith Bisphosphonates in Children and Adolescents With Osteogenesis Imperfec
 ta\n\nPrimary completion date: 2027-05-04 (estimated)\nOriginally planned:
  2027-02-22 (+2.3 months)\nPhase 3 · Rare · Osteogenesis Imperfecta\nEnr
 ollment: 111 · Sites: 65\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://trialsonar.netlify.app/radar.html?nct=NCT05972551\nhttps://clinical
 trials.gov/study/NCT05972551
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05972551
CATEGORIES:Rare,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871409-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:MARITIME-PEN readout (P3) · Amgen $AMGN
DESCRIPTION:Home Self-administration of Maridebart Cafraglutide With Autoin
 jector in Adults Living With Obesity or Overweight\n\nPrimary completion d
 ate: 2027-06-16 (estimated)\nPhase 3 · Cardio-Met · Obesity\, Overweight
 \nEnrollment: 230 · Sites: 25\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07871409\nhttps://cli
 nicaltrials.gov/study/NCT07871409
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07871409
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03969329-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Etelcalcetide readout (P3) · Amgen $AMGN
DESCRIPTION:A Phase 3 Study of Etelcalcetide in Children With Secondary Hyp
 erparathyroidism Receiving Hemodialysis\n\nPrimary completion date: 2027-0
 6-30 (estimated)\nOriginally planned: 2022-06-30 (+60.0 months)\nPhase 3 
 · Cardio-Met · Secondary Hyperparathyroidism\nEnrollment: 24 · Sites: 2
 3\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT03969329\nhttps://clinicaltrials.gov/study/NCT0396
 9329
URL:https://trialsonar.netlify.app/radar.html?nct=NCT03969329
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05920356-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sotorasib readout (P3) · Amgen $AMGN
DESCRIPTION:A Study Evaluating Sotorasib Platinum Doublet Combination Versu
 s Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Pa
 rticipants With Stage IV or Advanced Stage…\n\nPrimary completion date: 
 2027-06-30 (estimated)\nOriginally planned: 2025-12-04 (+18.8 months)\nPha
 se 3 · Oncology · Non-Small Cell Lung Cancer (NSCLC)\nEnrollment: 750 ·
  Sites: 418\n\nPrimary completion = last participant's primary-endpoint da
 ta collected\; topline results usually follow weeks to months later. Spons
 or-reported\, often an estimate. Not investment advice.\n\nhttps://trialso
 nar.netlify.app/radar.html?nct=NCT05920356\nhttps://clinicaltrials.gov/stu
 dy/NCT05920356
URL:https://trialsonar.netlify.app/radar.html?nct=NCT05920356
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321601-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270718
DTEND;VALUE=DATE:20270719
SUMMARY:Avacopan readout (P3) · Amgen $AMGN
DESCRIPTION:Study to Evaluate Avacopan in Combination With a Rituximab or C
 yclophosphamide-containing Regimen\, in Children From 6 Years to < 18 Year
 s of Age With AAV.\n\nPrimary completion date: 2027-07-18 (estimated)\nOri
 ginally planned: 2030-04-28 (-33.3 months)\nPhase 3 · Immuno · Vasculiti
 s\nEnrollment: 19 · Sites: 34\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT06321601\nhttps://cli
 nicaltrials.gov/study/NCT06321601
URL:https://trialsonar.netlify.app/radar.html?nct=NCT06321601
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614776-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:ABP 938 8 mg readout (P3) · Amgen $AMGN
DESCRIPTION:A Study to Evaluate Efficacy\, Safety\, and Immunogenicity With
  ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovasc
 ular Age-related Macular Degeneration\n\nPrimary completion date: 2027-07-
 31 (estimated)\nPhase 3 · Eye · Neovascular Age-related Macular Degenera
 tion\, nAMD\nEnrollment: 304 · Sites: 101\n\nPrimary completion = last pa
 rticipant's primary-endpoint data collected\; topline results usually foll
 ow weeks to months later. Sponsor-reported\, often an estimate. Not invest
 ment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07614776\
 nhttps://clinicaltrials.gov/study/NCT07614776
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07614776
CATEGORIES:Eye,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225686-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:MARITIME-OSA-1 readout (P3) · Amgen $AMGN
DESCRIPTION:Maridebart Cafraglutide Versus Placebo in Adult Participants Wi
 th Obstructive Sleep Apnea on Positive Airway Pressure Therapy\n\nPrimary 
 completion date: 2027-08-20 (estimated)\nOriginally planned: 2027-09-29 (-
 1.3 months)\nPhase 3 · Cardio-Met · Obesity\, Obstructive Sleep Apnea\nE
 nrollment: 250 · Sites: 61\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://trialsonar.netlify.app/radar.html?nct=NCT07225686\nhttps://clinic
 altrials.gov/study/NCT07225686
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07225686
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441252-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270825
DTEND;VALUE=DATE:20270826
SUMMARY:Maridebart cafraglutide readout (P2) · Amgen $AMGN
DESCRIPTION:A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglut
 ide in Adults Living With Elevated Liver Fat and Obesity or Overweight\n\n
 Primary completion date: 2027-08-25 (estimated)\nOriginally planned: 2027-
 09-29 (-1.1 months)\nPhase 2 · Cardio-Met · Overweight or Obesity and El
 evated Liver Fat\nEnrollment: 180 · Sites: 23\n\nPrimary completion = las
 t participant's primary-endpoint data collected\; topline results usually 
 follow weeks to months later. Sponsor-reported\, often an estimate. Not in
 vestment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT07441
 252\nhttps://clinicaltrials.gov/study/NCT07441252
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07441252
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226765-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:MARITIME-OSA-2 readout (P3) · Amgen $AMGN
DESCRIPTION:Maridebart Cafraglutide Versus Placebo in Adult Participants Wi
 th Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy\n
 \nPrimary completion date: 2027-08-30 (estimated)\nPhase 3 · Neuro · Obs
 tructive Sleep Apnea\nEnrollment: 250 · Sites: 57\n\nPrimary completion =
  last participant's primary-endpoint data collected\; topline results usua
 lly follow weeks to months later. Sponsor-reported\, often an estimate. No
 t investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT0
 7226765\nhttps://clinicaltrials.gov/study/NCT07226765
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07226765
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778316-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:DeLLphi-315 readout (P3) · Amgen $AMGN
DESCRIPTION:Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small
  Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)\n
 \nPrimary completion date: 2027-09-24 (estimated)\nPhase 3 · Oncology · 
 Small Cell Lung Cancer\nEnrollment: 400 · Sites: 9\n\nPrimary completion 
 = last participant's primary-endpoint data collected\; topline results usu
 ally follow weeks to months later. Sponsor-reported\, often an estimate. N
 ot investment advice.\n\nhttps://trialsonar.netlify.app/radar.html?nct=NCT
 07778316\nhttps://clinicaltrials.gov/study/NCT07778316
URL:https://trialsonar.netlify.app/radar.html?nct=NCT07778316
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
